The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2021 | Measuring MRD: methods and challenges
Jill Corre, PharmD, PhD, of L’Institut Universitaire du Cancer de Toulouse-Oncopole, Centre Hospitalier Universitaire, Toulouse, France, gives an overview on the tools available for the assessment of measure measurable residual disease (MRD) in patients with multiple myeloma, such as next generation sequencing (NGS) and flow cytometry. Dr Corre explains the difference between the methods, reporting that it is often difficult to directly compare results obtained from different methods. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
